Stock Events

Stock Events

Reviva Pharmaceuticals 

$0.5550
179
+$0.00+0% Friday 19:51

Statistics

Day High
0.555
Day Low
0.51
52W High
17.2
52W Low
0.262
Volume
9,945
Avg. Volume
50,371
Mkt Cap
7.11M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.89
-1.3
-0.71
-0.12
Expected EPS
-0.29
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-19.87MNet Income

Analyst Ratings

0.00Average Price Target
The highest estimate is 0.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RVPH. It's not an investment recommendation.
NVIDIA
30
NVDA
Apple
17
AAPL
Tesla
16
TSLA
Amazon
16
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes develops therapies for serious mental illness, overlapping with Reviva Pharmaceuticals' focus areas.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
ACADIA Pharmaceuticals specializes in central nervous system disorders, including treatments for psychiatric conditions, competing with Reviva's product pipeline.
BridgeBio Pharma
BBIO
Mkt Cap14.97B
BridgeBio Pharma targets genetic diseases and cancers, some of which involve neurological components, indirectly competing with Reviva's neurological focus.
Insmed
INSM
Mkt Cap25.89B
Insmed incorporates novel approaches to treat serious and rare diseases, including lung and neurological conditions, making it a competitor.
Axsome Therapeutics
AXSM
Mkt Cap10.42B
Axsome Therapeutics works on central nervous system disorders, including depression and migraine, areas Reviva is also targeting.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurology, neurodegenerative diseases, and multiple sclerosis, areas that overlap with Reviva's interests in neurological disorders.
AMGEN
AMGN
Mkt Cap233.78B
Amgen, with a broader focus, has ventured into neuroscience, including treatments for migraine, which could compete with Reviva's neurological drug development.

About

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Show more...
CEO
Laxminarayan Bhat
Employees
14
Country
United States
ISIN
US76152G2093

Listings

OTC Link
US
RVPH
BOATS
BOATS
RVPH.BOATS

0 Comments

Share your thoughts

FAQ

What is Reviva Pharmaceuticals stock price today?▼
The current price of RVPH is $0.56 USD — it has increased by +0% in the past 24 hours. Watch Reviva Pharmaceuticals stock price performance more closely on the chart.
What is Reviva Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Reviva Pharmaceuticals stocks are traded under the ticker RVPH.
Is Reviva Pharmaceuticals stock price growing?▼
RVPH stock has risen by +7.77% compared to the previous week, the month change is a +8.82% rise, over the last year Reviva Pharmaceuticals has showed a -93.68% decrease.
What is Reviva Pharmaceuticals market cap?▼
Today Reviva Pharmaceuticals has the market capitalization of 7.11M
When is the next Reviva Pharmaceuticals earnings date?▼
Reviva Pharmaceuticals is going to release the next earnings report on November 16, 2026.
What were Reviva Pharmaceuticals earnings last quarter?▼
RVPH earnings for the last quarter are -0.19 USD per share, whereas the estimation was -0.39 USD resulting in a +50.65% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Reviva Pharmaceuticals revenue for the last year?▼
Reviva Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Reviva Pharmaceuticals net income for the last year?▼
RVPH net income for the last year is -19.87M USD.
How many employees does Reviva Pharmaceuticals have?▼
As of September 05, 2026, the company has 14 employees.
In which sector is Reviva Pharmaceuticals located?▼
Reviva Pharmaceuticals operates in the Health & Wellness sector.
When did Reviva Pharmaceuticals complete a stock split?▼
The last stock split for Reviva Pharmaceuticals was on March 09, 2026 with a ratio of 1:20.
Where is Reviva Pharmaceuticals headquartered?▼
Reviva Pharmaceuticals is headquartered in Cupertino, United States.